Barclays
TNDM icon

Barclays’s Tandem Diabetes Care TNDM Stock Holding History

Barclays’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-90,600
Closed -$1.74M – 5632
2026
Q1 		$1.74M Buy
+90,600
New +$1.97M ﹤0.01% 2436
2024
Q2 		– Sell
-20,800
Closed -$737K – 5298
2024
Q1 		$737K Buy
+20,800
New +$557K ﹤0.01% 3342
2018
Q4 		– Sell
-88,000
Closed -$3.77M – 7326
2018
Q3 		$3.77M Buy
+88,000
New +$3.07M ﹤0.01% 2119

Other funds holding TNDM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Barclays's TNDM Position: Q2 2026 in Review

Barclays reduced its Tandem Diabetes Care (TNDM) stake by 17% in Q2 2026, selling an estimated $1.24M and leaving 350,429 shares worth $5.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

Barclays first reported a position in TNDM in Q4 2013 and has held it in 48 quarters since. The position peaked at $20.2M in Q4 2025. 273 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

  • Barclays held 350,429 shares of Tandem Diabetes Care worth $5.29M as of Q2 2026.
  • Barclays sold 70,807 Tandem Diabetes Care shares in Q2 2026, an estimated $1.24M.
  • Tandem Diabetes Care made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1806 holding.
  • Barclays first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 48 quarters since.
  • Barclays's Tandem Diabetes Care position peaked at $20.2M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.